Most of the confident information circulating about research peptides is wrong in one of a small number of specific, repeatable ways. None of these errors is exotic. They persist because they are rarely stated plainly, and because almost everyone with an audience in this space has a reason not to state them.
Here are the five that account for most of it.
1. Treating a rodent dose as a human dose
This is the most common quantitative error, and it is not a matter of rounding.
Metabolic rate does not scale linearly with body mass. Converting a dose between species by milligrams per kilogram overestimates the equivalent dose in the larger species, often by a large factor. Regulatory practice uses body-surface-area scaling instead. FDA's guidance on estimating starting doses in initial clinical trials converts an animal dose to a human equivalent dose using species-specific Km factors — approximately 3 for mouse, 6 for rat, 37 for human:
HED = animal dose (mg/kg) × (animal Km ÷ human Km)
A dose in mice therefore corresponds to roughly one twelfth of that figure in mg/kg terms for a human; from rats, roughly one sixth. A protocol derived by taking a mouse study's mg/kg number directly is off by an order of magnitude before any other consideration.
And BSA scaling is itself only a rough first approximation for a starting dose. It does not account for differences in absorption, protein binding, metabolism, receptor distribution, or clearance between species.
2. Reading purity as identity
"99% pure" and "this is the compound named on the label" are separate claims established by separate methods.
HPLC measures how much of the detected material is a single component, relative to total peak area at one detection wavelength. It does not confirm what that component is, and it cannot count material that does not absorb at that wavelength — salts and residual solvents included.
Identity requires mass spectrometry. A certificate with a high purity figure and no mass confirmation shows a sample is homogeneous. It does not show it is the right molecule.
3. Treating preclinical results as established effects
A large share of the literature cited in community discussion is in vitro or rodent work. That research is legitimate and it is how questions get raised — but a preclinical finding is a reason to investigate further, not evidence of a clinical effect.
The attrition rate between promising preclinical results and demonstrated clinical efficacy is severe across all of drug development, and it is severe for reasons that apply squarely here: model organisms differ in physiology, cell-culture concentrations rarely correspond to achievable tissue concentrations, and endpoints in animal models are frequently surrogates rather than outcomes.
When a claim traces back to a rodent study, the honest description is "this was observed in rats," not "this works."
4. Trusting "third-party tested" as a defined term
It isn't one. No standard, no accrediting body, and no definition attaches to the phrase. It is compatible with genuine independent testing at an accredited laboratory, and equally compatible with a seller testing their own material.
The distinguishing question is not whether the phrase appears in the marketing copy. It is whether a named, contactable laboratory appears on the certificate. If no independent party is identified, none was involved.
5. Reading anecdote as evidence
Forum reports share a set of structural problems that make them unreliable as evidence regardless of how numerous or sincere they are: no control, no blinding, no verification that the material was what it claimed to be, self-selected reporting, and strong survivorship bias — people who experience nothing generally stop posting.
The specific trap in this field is that reported experience is frequently attributed to a compound when the material's identity and purity were never established. If the certificate was recycled, drawn, or absent, the report is not evidence about the compound at all. It is evidence about an unknown substance.
The common thread
Four of these five errors are verification failures rather than pharmacology failures. They come from accepting a claim without asking which method produced it, in what species, at what dose, verified by whom.
That is a solvable problem, and it is largely solved by reading the certificate before reading the marketing.
Related reading
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication